T1	Haplotype	31 47	UGT1A haplotypes
T2	Pharmacokinetic_phenotype	56 137	area under concentration curve ratio ( SN-38 glucuronide / SN -38 ) or toxicities
T3	Pharmacodynamic_phenotype	56 142	area under concentration curve ratio ( SN-38 glucuronide / SN -38 ) or toxicities were
T4	Disease	168 183	cancer patients
T5	Chemical	197 219	irinotecan as a single
T6	Chemical	257 258	.
R1	isAssociatedWith	Arg1:T1	Arg2:T2
R2	isAssociatedWith	Arg1:T1	Arg2:T3
R3	isAssociatedWith	Arg1:T1	Arg2:T4
R4	isAssociatedWith	Arg1:T1	Arg2:T5
R5	isAssociatedWith	Arg1:T1	Arg2:T6
R6	isAssociatedWith	Arg1:T2	Arg2:T1
R7	isAssociatedWith	Arg1:T2	Arg2:T3
R8	isAssociatedWith	Arg1:T2	Arg2:T4
R9	isAssociatedWith	Arg1:T2	Arg2:T5
R10	isAssociatedWith	Arg1:T2	Arg2:T6
R11	isAssociatedWith	Arg1:T3	Arg2:T1
R12	isAssociatedWith	Arg1:T3	Arg2:T2
R13	isAssociatedWith	Arg1:T3	Arg2:T4
R14	isAssociatedWith	Arg1:T3	Arg2:T5
R15	isAssociatedWith	Arg1:T3	Arg2:T6
R16	isAssociatedWith	Arg1:T4	Arg2:T1
R17	isAssociatedWith	Arg1:T4	Arg2:T2
R18	isAssociatedWith	Arg1:T4	Arg2:T3
R19	treats	Arg1:T4	Arg2:T6
R20	treats	Arg1:T5	Arg2:T1
R21	treats	Arg1:T5	Arg2:T2
R22	treats	Arg1:T5	Arg2:T3
R23	treats	Arg1:T5	Arg2:T4
R24	treats	Arg1:T5	Arg2:T6
R25	isAssociatedWith	Arg1:T6	Arg2:T1
R26	isAssociatedWith	Arg1:T6	Arg2:T2
R27	isAssociatedWith	Arg1:T6	Arg2:T3
R28	treats	Arg1:T6	Arg2:T4
R29	influences	Arg1:T6	Arg2:T5
